Efficacy And Safety of Sauropus Androgynous in the Treatment of Aphthous Stomatitis- A Placebo Controlled Double Blind Trial

Authors

Dr. Ashok Shenoy K¹, Dr. Mukta N Chowta², Dr. Nandita Shenoy³
Dr. Prabha Adhikari⁴

¹Professor and Head, Department of Pharmacology, Kasturba Medical College, Mangalore
Affiliated to Manipal University

²Professor, Department of Pharmacology, Kasturba Medical College, Mangalore
Affiliated to Manipal University

³Associate Professor, Department of Oral medicine and Radiology, Manipal College of Dental Sciences
Mangalore: Affiliated to Manipal University.

⁴Professor, Department of Medicine, Kasturba Medical College, Mangalore, Affiliated to Manipal University

Correspondence Authors

Dr. Nandita Shenoy
Associate Professor, Department of Oral medicine and Radiology, Manipal College of Dental Sciences
Light House Hill Road, Mangalore: Affiliated to Manipal University
Email-nandita.shenoy@gmail.com

Abstract

Recurrent aphthous stomatitis (RAS) is a common inflammatory condition of unknown aetiology, although a variety of predisposing and other risk factors have been identified. Manifestation of the disease can range from mild to severe and, in extreme cases, even hinder a person’s ability to eat, thereby compromising the patient’s nutritional status. The cause of RAS is unknown, although several factors are suspected including genetics, stress, nutritional deficiencies, diet, hormonal changes, and immunological disorders. Due to its varied etiology, it is difficult to find a definitive cure and hence the current management protocol is aimed towards ameliorating the symptoms. Sauropus androgynous (SA) is a member of the family Phyllanthaceae. The aim of the present study was to carry out randomized, placebo controlled investigation into the efficacy of Sauropus androgynous leaves in patients with RAS. One hundred adult patients who presented with RAS and healthy otherwise were included in the study. A clinical diagnosis of RAS was made based on the presence of painful ulcers on an erythematous base with duration less than 48 hours. Patients were excluded if they presented with any underlying systemic disorder, suffering from an uncorrected dietary defect, or had a history of probable sensitivity to mouthwash or toothpaste. Informed consent was obtained and general history, history with reference to ulcer number, duration, degree of pain. Past history of similar ulcers, time taken to heal was recorded. SA in both forms offered advantages over steroids in our study and is safe in all patients including infants and pregnant women, in whom there may be reluctance to use steroids.
INTRODUCTION

Recurrent aphthous stomatitis (RAS) is a common inflammatory condition of unknown aetiology, although a variety of predisposing and other risk factors have been identified. Manifestation of the disease can range from mild to severe and, in extreme cases, even hinder a person’s ability to eat, thereby compromising the patient’s nutritional status.

The cause of RAS is unknown, although several factors are suspected including genetics, stress, nutritional deficiencies, diet, hormonal changes, and immunological disorders. Due to its varied etiology, it is difficult to find a definitive cure and hence the current management protocol is aimed towards ameliorating the symptoms.

Treatment for RAS is symptomatic; the goals being to decrease pain, healing time, reduce the number and size of the ulcer, and to increase disease-free periods. Current treatment options include topical agents, systemic and topical steroids, cauterization, antibiotics, active enzymes, laser treatments and combination therapy.

Sauropus androgynous (SA) is a member of the family Phyllanthaceae. This plant is spread in India and other south east Asian countries. In India, it is widely known as Multi Vitamin Leaf and is used in cooking and as medicinal plant, as different parts of this plant have different usefulness. Leaves and roots of SA can be used to relieve fever, urinary problems, earache and also as a slimming agent.

The aim of the present study was to carry out randomized, placebo controlled investigation into the efficacy of Sauropus androgynous leaves in patients with RAS.

MATERIALS AND METHODS

One hundred adult patients who presented with RAU and healthy otherwise were included in the study. A clinical diagnosis of RAS was made based on the presence of painful ulcers on an erythematous base with duration less than 48 hours. Patients were excluded if they presented with any underlying systemic disorder, suffering from an uncorrected dietary defect, or had a history of probable sensitivity to mouthwash or toothpaste.

Informed consent was obtained and general history, history with reference to ulcer number, duration, degree of pain. Past history of similar ulcers, time taken to heal was recorded.

Assessment of ulcer was done using the following parameters:

Assessment of ulcer size:
- No ulcer: 0
- 1-5 mm: 1
- 6-10 mm: 2
- >10 mm: 3

Assessment of ability to take food:
- Ability to eat normal food: 0
- Ability to eat bland diet only: 1
- Ability to take liquids only: 2
Laboratory Investigations included:
Hemoglobin, Total WBC Counts, Differential Count, Platelet count, Random Blood Sugar, Liver Function Test and Peripheral smear

Study Medication and Dose for test group
Randomized double-blind placebo controlled trial was conducted on 60 patients. Patients were divided into four groups.

Group 1: Fresh leaves of SA were shade dried and converted into capsule containing 375 mg of the leaf extract to be given three times a day orally.

Group 2: Fresh leaves of SA were shade dried and converted into an ointment and patients were instructed how to apply the ointment for subsequent applications.

Group 3: Control group was given Vitamin B complex preparation.

Group 4: Placebo ointment were given and patients were instructed how to apply the ointment for subsequent applications.

Table 1: Treatment allocations

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Route</th>
<th>Dose, frequency and Duration</th>
<th>No of patients</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin B Complex</td>
<td>Capsule</td>
<td>Oral</td>
<td>1 capsule TID for 7 days</td>
<td>15</td>
<td>Control</td>
</tr>
<tr>
<td>Sauropus</td>
<td>Capsule</td>
<td>Oral</td>
<td>375 mg TID for 7 days</td>
<td>15</td>
<td>Efficacy and safety</td>
</tr>
<tr>
<td>Placebo (Sucralfate Gel)</td>
<td>Ointment</td>
<td>Topical</td>
<td>Sufficient quantity TID for 7 days</td>
<td>15</td>
<td>Control</td>
</tr>
<tr>
<td>Sauropus</td>
<td>Ointment</td>
<td>Topical</td>
<td>Sufficient quantity TID for 7 days</td>
<td>15</td>
<td>Efficacy and safety</td>
</tr>
</tbody>
</table>

RESULTS
A total of 60 patients were enrolled into the study and completed the first supervised part of the study. Demographic details of patients together with details of their baseline ulcer history are shown in Table 1. The number of ulcers and baseline soreness scores were similar for the two treatment groups (SA capsule and SA ointment) (P > 0.05). Following initial application, patients in both treatment groups reported a rapid reduction (P ¼ 0.0004) in their discomfort scores and size of the ulcer. Ability to eat improved with treatment as shown in Table 2.
Table 1: Demographic characteristics of patients

<table>
<thead>
<tr>
<th></th>
<th>Age (Years)</th>
<th>Frequency (Monthly)</th>
<th>Number of ulcers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test Drug Capsule</td>
<td>26.5 (6.4)</td>
<td>0.5 (0.7)</td>
<td>2 (1.4)</td>
</tr>
<tr>
<td>B Complex Capsule</td>
<td>30.6 (16.9)</td>
<td>2.3 (1.5)</td>
<td>3.7 (3.2)</td>
</tr>
<tr>
<td>Test Drug ointment</td>
<td>44 (8.2)</td>
<td>2.3 (1.5)</td>
<td>2.7 (0.6)</td>
</tr>
<tr>
<td>Sucralfate ointment</td>
<td>30.6 (13.2)</td>
<td>2.5 (1.1)</td>
<td>1.5 (0.8)</td>
</tr>
</tbody>
</table>

Table 2: Score reduction among various groups

<table>
<thead>
<tr>
<th>Group</th>
<th>Size</th>
<th>Pain</th>
<th>Diameter</th>
<th>Induration</th>
<th>Ability to eat</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sauropus Capsule</td>
<td>0.5 (0.7)</td>
<td>2.0 (1.4)</td>
<td>0.6 (0.8)</td>
<td>2.3 (1.5)</td>
<td>1 (0)</td>
<td>4.7 (1.0)</td>
</tr>
<tr>
<td>Vitamin B Complex</td>
<td>1.39 (1.1)</td>
<td>2.0 (0.9)</td>
<td>2.3 (1.5)</td>
<td>1.5 (1.6)</td>
<td>1.5 (1.6)</td>
<td>7.8 (4.5)</td>
</tr>
<tr>
<td>Sauropus Ointment</td>
<td>0.9 (0.2)</td>
<td>2.3 (0.6)</td>
<td>1.6 (0.5)</td>
<td>1.6 (1.3)</td>
<td>1 (0)</td>
<td>7.7 (1.5)</td>
</tr>
<tr>
<td>Placebo (Sucralfate Gel)</td>
<td>0.9 (0.8)</td>
<td>2.0 (1.4)</td>
<td>0.6 (0.8)</td>
<td>1.3 (0.5)</td>
<td>0.8 (0.4)</td>
<td>5.0 (1.3)</td>
</tr>
</tbody>
</table>

Figure 1: Healing time comparison
DISCUSSION

Traditional medicine is an important source of potentially useful compounds for the development of chemotherapeutic agents. A wide range of medicinal plant parts is used for extract as raw drugs and they possess varied medicinal properties. SA, also known as star gooseberry, or sweet leaf, is a shrub grown in some tropical regions as a leaf vegetable. In India, as it is known Multivitamin Plant, it is an excellent source of vitamins A, B, C, carotenoid and also it has high nutritive value and contains phytochemicals which can act as antioxidant.

Studies have proved that the leaves of SA has high levels of provitamin A carotenoids, vitamins B and C, protein and minerals. SA plant extracts have showed to have anti-inflammatory effects and antioxidant activity as well.

Our results very clearly indicated that SA capsule and Ointment were better than the control group in terms of the parameters evaluated. Parameters used to evaluate the outcome of treatments in the management of oral ulceration included the incidence of ulceration, the duration of ulceration is the mean duration of individual ulcers, pain perception and the quality of life improved comparatively.

Our patients showed a good compliance indicating the acceptability of the product in either form. The most significant outcome of this study was the sustained reduction in pain scores after application of Topical SA and Topical placebo (Sucralfate Gel). Both preparations caused significant, immediate reduction in discomfort following application. This would suggest some protective or barrier action arising from placement of this specific ointment. The effects seemed to last for at least 30 min. This protective or barrier property because of topical application may support further the use of topical medications in the management of symptoms arising from RAU. Topical medications appear to be the first choice treatment for RAU. Such preparations have its own limitations though in terms of mode of drug delivery, subsequent compliance and retention on the oral mucosa. These features probably impact significantly on the efficacy of the agent, but do present challenges to the pharmaceutical industry for appropriate development.

We also observed a reduction in the number of ulcers over time in SA capsule group in comparison to the placebo group which speaks in terms of the efficacy of SA as an immunity enhancer.

Topical steroids are commonly used in the management of RAU. Randomized controlled Trial on topical steroids demonstrated a significant reduction in pain compared with placebo, but showed no effect on reducing the frequency of RAU occurrence. Other similar studies demonstrated weak evidence of a reduction in pain and ulcer duration, without significant adverse effects. Nevertheless, SA in both forms offers advantages over steroids in that it is safe in all patients including infants and...
pregnant women, in whom there may be reluctance to use steroids. This study with a herbal medication is probably the first and a right step in the direction of searching for novel and more effective therapeutic agent in the prevention of development and recurrence of Recurrent Aphthous Stomatitis and more studies with larger groups have to be undertaken.

REFERENCES


